VTVT•vTv Therapeutics reported a third-quarter net loss of $11.6 million and no revenue, with operating expenses of $12.43 million. The company completed enrollment in its Phase 3 CATT1 trial and expects topline results in mid-2027.
vTv Therapeutics said its third-quarter net loss widened to $11.6 million, with no revenue. Operating expenses rose to $12.43 million, mainly due to continued investment in the Phase 3 CATT1 trial; higher share-based compensation and payroll-related expenses also increased general and administrative costs.
The company completed enrollment in the Phase 3 CATT1 trial and expects topline results in mid-2027. It said a Phase 2a Hybrid CATT1 study is intended to inform future Phase 3 research in hybrid closed-loop type 1 diabetes.
